Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.
about
A P53 target gene, PIG11, contributes to chemosensitivity of cells to arsenic trioxideArsenic exposure and toxicology: a historical perspectiveArsenic exposure predicts bladder cancer survival in a US populationKML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress PathwayHeavy metal toxicity and the environmentInhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancerEffect of arsenic trioxide on vascular endothelial cell proliferation and expression of vascular endothelial growth factor receptors Flt-1 and KDR in gastric cancer in nude mice.Arsenic trioxide induces apoptosis of human gastrointestinal cancer cells.Colorectal cancer and NF-κB signaling pathwayArsenic trioxide suppresses paclitaxel-induced mitotic arrest.Comparison of As(2)O(3) and As(4)O(6) in the detection of SiHa cervical cancer cell growth inhibition pathway.Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancersSodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyThe effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cellsA novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.Galectin-3 as a marker and potential therapeutic target in breast cancerComparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors.Arsenic sulfide as a potential anti‑cancer drug.Arsenic trioxide: acute promyelocytic leukemia and beyond.The hedgehog/Gli signaling paradigm in prostate cancerCarcinogenic and systemic health effects associated with arsenic exposure--a critical review.Novel therapies for patients with chronic myeloid leukemia.Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administrationSodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responsesDownregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.The sensitivity of digestive tract tumor cells to As2O3 is associated with the inherent cellular level of reactive oxygen species.Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide.Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells.Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest.Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.Arsenic trioxide inhibits glioma cell growth through induction of telomerase displacement and telomere dysfunction.Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cellsTetraarsenic oxide-mediated apoptosis in a cervical cancer cell line, SiHa.IκBζ: an emerging player in cancer.Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite.Inhibition of the heat shock response by PI103 enhances the cytotoxicity of arsenic trioxide.
P2860
Q28269275-9A7D02F5-597F-4804-9F72-AC4A85807E2BQ28392204-0AF143A7-34D6-4165-AF32-E5A40FEBAD33Q28397390-9B85DE6F-A98F-4C6E-9DC3-4CC6270033DEQ28547789-18D496CF-D0AC-4753-BCC1-5CDA5EECB944Q28654255-35D09C10-999A-40E3-9B19-70C52E6587A1Q30436959-B7B939F8-E35E-46F8-B0B6-A867689FB739Q33258696-B8B5DBE4-DDC8-4F4A-9AAD-5EEBC961EA21Q33312494-250D2437-7C64-44C9-9DAA-D124AC28E763Q33594955-CF99D7A3-0EB0-46FC-8446-047817EAB913Q33596306-D6C6CFB4-24F7-4AA5-A740-D56BDEF24E40Q33665774-70C6CBFF-DC0C-46D7-B38E-C58238F9961DQ33746867-BFA29238-1FBD-4A9D-BEEB-9CB644045CDDQ33768666-C31DF559-DBB4-4E69-9DAC-6D7B311D8F84Q33940195-AB04EEE0-9908-44AA-93D5-9498A8DFA649Q33962155-F8543D7F-F426-4C61-A31C-2082240EA40CQ33965775-9B6C3D49-7371-44E4-97DE-248DD66847C8Q34145056-7BA5B303-2290-4328-89B5-49EB0E3DCF0CQ34257030-28393678-DC91-4FAE-B691-4073E55BE122Q34430810-4D5CD11E-D3FA-41B1-86CF-03A86B6F2AA9Q34673252-D335E3B5-3DA1-47B8-91BE-2802E977762CQ34980350-DF8F6EA3-0CBD-4C88-B4CF-0A470EA7F267Q35109835-ADA3B856-19E6-4CCC-B661-F88D19F38373Q35571581-A0450076-9C2F-43A9-A66C-29FA42C5B331Q35728742-F4CB0AB6-A2E6-419E-A699-8D6B02174981Q35830597-69C5F73B-3439-4B06-9794-24D4ECE048D6Q35892810-5F041840-1E90-4187-9FB8-6A69F352D68EQ36224699-57401308-ABDB-4847-91BB-4B56D51E20A6Q36309105-87A7709A-3F3F-416D-892D-84C71C438D96Q36509566-FA8FA95D-EC57-44EB-91E5-698F035090A3Q36601383-CFF47A2E-A590-43BB-82BC-DFAF096A9856Q36646486-204F78C5-4C66-4EC7-8854-D28A6D43BC40Q36775161-5BA5CF54-98BD-412B-97EC-54223E60A794Q36824250-AD7A6C13-74B1-4F6B-B951-C8D40FD5D4ECQ37022265-D4F984E6-511A-46D4-9830-9436A8DA1B31Q37085878-F9D77864-A30A-4834-8FA2-EA0A0D72AAB8Q37148048-3D08BF27-59E7-4C00-B380-50073FBC0603Q37449189-D6AFA6D5-FEE8-4CCF-9B15-0F1FD5658E45Q37662411-AB5842F9-6D5A-4D53-A998-97FBC6EB17E3Q38295592-E9541FE3-11C8-4349-9555-28E8333921A1Q38326197-3559179E-5862-4359-8AC2-71EA94B2E5B6
P2860
Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical trials of arsenic tri ...... earch and Development Studies.
@ast
Clinical trials of arsenic tri ...... earch and Development Studies.
@en
Clinical trials of arsenic tri ...... earch and Development Studies.
@nl
type
label
Clinical trials of arsenic tri ...... earch and Development Studies.
@ast
Clinical trials of arsenic tri ...... earch and Development Studies.
@en
Clinical trials of arsenic tri ...... earch and Development Studies.
@nl
prefLabel
Clinical trials of arsenic tri ...... earch and Development Studies.
@ast
Clinical trials of arsenic tri ...... earch and Development Studies.
@en
Clinical trials of arsenic tri ...... earch and Development Studies.
@nl
P1433
P1476
Clinical trials of arsenic tri ...... earch and Development Studies.
@en
P2093
P356
10.1634/THEONCOLOGIST.6-SUPPL_2-22
P478
P577
2001-01-01T00:00:00Z